T. Rowe Price Associates’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.15M | Buy |
|
|||||
|
2025
Q1 | $1.15M | Buy |
|
|||||
|
2024
Q4 | $644K | Sell |
|
|||||
|
2024
Q3 | $1.14M | Buy |
|
|||||
|
2024
Q2 | $919K | Buy |
|
|||||
|
2024
Q1 | $269K | Buy |
|
|||||
|
2023
Q4 | $231K | Sell |
|
|||||
|
2023
Q3 | $386K | Buy |
|
|||||
|
2023
Q2 | $394K | Sell |
|
|||||
|
2023
Q1 | $401K | Buy |
|
|||||
|
2022
Q4 | $474K | Buy |
|
|||||
|
2022
Q3 | $830K | Buy |
|
|||||
|
2022
Q2 | $2.22M | Sell |
|
|||||
|
2022
Q1 | $3.26M | Sell |
|
|||||
|
2021
Q4 | $31.1M | Sell |
|
|||||
|
2021
Q3 | $96.6M | Buy |
|
|||||
|
2021
Q2 | $82.7M | Sell |
|
|||||
|
2021
Q1 | $149M | Buy |
|
|||||
|
2020
Q4 | $38.6M | Buy |
|
|||||
|
2020
Q3 | $20.7M | Sell |
|
|||||
|
2020
Q2 | $19.1M | Buy |
|
|||||
|
2019
Q1 | – | Sell |
|
|||||
|
2018
Q4 | $5.17M | Buy |
|
|||||
|
2017
Q2 | – | Sell |
|
|||||
|
2017
Q1 | $58K | Hold |
|
|||||
|
2016
Q4 | $58K | Hold |
|
|||||
|
2016
Q3 | $95K | Sell |
|
|||||
|
2016
Q2 | $171M | Buy |
|
|||||
|
2016
Q1 | $121M | Buy |
|
|||||
|
2015
Q4 | $191M | Buy |
|
|||||
|
2015
Q3 | $151M | Buy |
|
|||||
|
2015
Q2 | $221M | Sell |
|
|||||
|
2015
Q1 | $164M | Buy |
|
|||||
|
2014
Q4 | $73.4M | Buy |
|
|||||
|
2014
Q3 | $49.7M | Buy |
|
|||||
|
2014
Q2 | $47.2M | Buy |
|
|||||
|
2014
Q1 | $14.5M | Sell |
|
|||||
|
2013
Q4 | $21.9M | Buy |
|
|||||
|
2013
Q3 | $13.5M | Buy |
|
|||||
|
2013
Q2 | $97K | Buy |
|